MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

BACKGROUND: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival. MAP17 (PDZK1IP1) is a small membrane-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrer, Irene, Quintanal-Villalonga, Álvaro, Molina-Pinelo, Sonia, Garcia-Heredia, Jose Manuel, Perez, Marco, Suárez, Rocío, Ponce-Aix, Santiago, Paz-Ares, Luis, Carnero, Amancio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098621/
https://www.ncbi.nlm.nih.gov/pubmed/30119639
http://dx.doi.org/10.1186/s13046-018-0871-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098621/
https://www.ncbi.nlm.nih.gov/pubmed/30119639
http://dx.doi.org/10.1186/s13046-018-0871-7

Ejemplares similares